🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

I am thrilled to announce that world-class physician scientist and leukemia researcher Dr. Marina Konopleva Marina Konopleva has joined us at Montefiore Einstein Cancer Center @AE_CancerCenter as the Director of the Leukemia Program, and Co-Director of our new Blood Cancer Institute !!

Had fun at the MDS walk in rainy Manhattan today. MDS Foundation does a great job raising funds for patients and research Aditi Shastri, MD Mani Mohindru, PhD Montefiore Health System Albert Einstein College of Medicine - Official

Our ASH 2022 abstract released - excited to share our experience with metronomically dosed weekly Decitabine+Venetoclax, a innovative pharmacodynamic approach in AML at this years meeting ash.confex.com/ash/2022/webpr… Ty to our Montefiore Health System team as well as Yogen Saunthararajah

Y’all hit that retweet button for me. Appreciate y’all!! #ProBowlVote #DaBears Justin Fields

.Aditi Shastri, MD is a physician-scientist exploring new treatments for myelodysplastic syndromes (MDS) & Acute Myeloid Leukemia (AML). She’s an advocate for equitable access to stem cell treatments, diversity in clinical trials, & #WomenInMedicine. #WomensHistoryMonth Albert Einstein College of Medicine - Official

x.com/i/spaces/1kvKp…

It is an honor to be among these highly accomplished women #leaders. Looking forward to this in-person event. #longwoodhealthcareleaders #biotech

Had a very #productive #strategicplanning #offsite session with my team! Covered many aspects including #unified vision, business #alignment , #priorities and #goals. #biotech

Congress | #EHA2023 | Poster Ioannis Mantzaris Montefiore Health System Albert Einstein College of Medicine - Official shares initial results from a phase Ib study assessing the safety and tolerability of different venetoclax doses with daunorubicin + cytarabine followed by high-dose cytarabine in pts with ND AML. #leusm

Montefiore Einstein Cancer Center investigators have developed a new treatment regimen for patients with MDS and AML. The strategy was found to be less toxic, as effective as the standard chemotherapy regimen, and more convenient for patients. More at bit.ly/3qSnUUq

Excited to see our work published in Clinical Cancer Research on our metronomic, low dose decitabine+venetoclax in MDS and AML! tinyurl.com/f746r3kb Thank you to Mendel Goldfinger Amit Verma Yogen Saunthararajah for making this possible

Hot off the press!!! So excited to collaborate with lead author Diego Adrianzen-Herrera, MD, MS on this exciting new publication Blood Advances Impact of pre-existing autoimmune disease on #MDS EinsteinSCI Montefiore Health System . Read below 👇🏾

Remarkable to see that our discoveries over 15 years ago would enable such tremendous advances for sickle cell disease and thalassemia!!! Incredible to think that the final sentence of our 2008 paper would be prophetic (science.org/doi/10.1126/sc…)... statnews.com/2023/11/16/u-k…

Proud of Arjun Gupta who took this concept as his original idea & ignited a movement in oncology Using a Real-Time Location System, his team demonstrates even the simplest of clinic appts can take up hours of patients' time academic.oup.com/oncolo/advance…

🔥 Our clinical trial of metronomic low-dose decitabine-ven in frontline MDS/ AML shows low tox, high efficacy & high response rate in TP53 mutant pts!! pubmed.ncbi.nlm.nih.gov/39316768/ Amit Verma Aditi Shastri, MD Ioannis Mantzaris Marina Konopleva Yogen Saunthararajah Montefiore Health System Albert Einstein College of Medicine - Official #leusm

DRREDDY Aurigene Oncology Limited announces promising results of Phase 1 study for India’s first trial for novel autologous CAR-T cell therapy for multiple myeloma.

Great to see promising results from India's first CAR-T trial for Myeloma! BCMA CAR-T shows good safety and efficacy and provides an excellent option for Indian patients. @AurigeneDiscov

Crispr modified CD70 allo CARs against T cell malignancies. Trial co-led by our outstanding Alex Sica in The Lancet Oncology Montefiore Health System Albert Einstein College of Medicine - Official thelancet.com/journals/lanon…

Ven can be safely used in combination with 7+3 chemotherapy for remission induction in patients with newly diagnosed AML. ow.ly/pZAa50VHuAi #clinicaltrialsandobservations #myeloidneoplasia